Key result
Clopidogrel is an effective and well-tolerated antiplatelet agent for the secondary prevention of ischemic events in patients with acute coronary syndromes.
Why the study?
Does clopidogrel reduce ischemic events in patients with acute coronary syndromes?
Does clopidogrel reduce ischemic events in patients with acute coronary syndromes?
This review summarizes the landmark evidence supporting clopidogrel for secondary prevention in ACS, highlighting the clinical database supporting the generic formulation Zyllt.
Answers are grounded in this paper and cite their sources.
Supports clopidogrel for ACS secondary prevention; confirms landmark randomized evidence via literature synthesis.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Ljevar et al. (2013) conducted a review in Acute coronary syndrome. Clopidogrel was evaluated. Clopidogrel is an effective and well-tolerated antiplatelet agent for the secondary prevention of ischemic events in patients with acute coronary syndromes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: